Human BACE-1 Protein
Catalog No: BACE1-HF001
- Species
- Human
- Expression System
- HEK293
- Tag
- an hFc (IgG1)
Product overview
Recombinant Human BACE-1 Protein is expressed in HEK293 cells with an hFc (IgG1) tag at the C-terminus. It contains amino acid residues Thr22-Thr457 (accession: NP_036236.1).
Product Details
- Molecular Aliases
- Beta-secretase 1; ASP2; Asp 2; BACE1; BACE; FLJ90568; HSPC104; KIAA1149; Memapsin-2; BACE-1; EC 3.4.23; EC 3.4.23.46;β-secretase 1;EC3.4.23; EC3.4.23.46;b-secretase 1
- Protein Length
- Thr22-Thr457
- Expression System
- HEK293
- Theoretical Molecular Weight
- The protein has a predicted MW of 75.2 kDa (pro-form) and 72.6 kDa (mature-form). Due to glycosylation, the protein migrates to 85-100 kDa based on Bis-Tris PAGE result.
- Purity
- > 95% as determined by Bis-Tris PAGE > 95% as determined by HPLC
- Endotoxin
- Less than 1 EU per ug by the LAL method.
- Buffer / Formulation
- Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
- State
- Lyophilized
- Storage Conditions
- -20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
- Reconstitution Advice
- Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.
Data Display
Human BACE-1 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human BACE-1 is greater than 95% as determined by SEC-HPLC.
Background
The beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1) initiates the generation of amyloid-β (Aβ), and the amyloid cascade leading to amyloid plaque deposition, neurodegeneration, and dementia in Alzheimer's disease (AD). Clinical failures of anti-Aβ therapies in dementia stages suggest that treatment has to start in the early, asymptomatic disease states.
References
- Neumann U, Ufer M, Jacobson LH, Rouzade-Dominguez ML, Huledal G, Kolly C, Lüönd RM, Machauer R, Veenstra SJ, Hurth K, Rueeger H, Tintelnot-Blomley M, Staufenbiel M, Shimshek DR, Perrot L, Frieauff W, Dubost V, Schiller H, Vogg B, Beltz K, Avrameas A, Kretz S, Pezous N, Rondeau JM, Beckmann N, Hartmann A, Vormfelde S, David OJ, Galli B, Ramos R, Graf A, Lopez Lopez C. The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease. EMBO Mol Med. 2018 Nov;10(11):e9316. doi: 10.15252/emmm.201809316. PMID: 30224383; PMCID: PMC6220303.
Have questions about this product?
Our technical team can help with product selection, application questions and order support.